LDH in the follow-up of stage I malignant melanoma

Campora, E; Repetto, Lazzaro; Giuntini, Patrizia; Bertelli, Gianfilippo; Amoroso, Domenico; Sertoli, Mario Roberto; Rosso, Riccardo

doi:10.1016/0277-5379(88)90266-0

Cited by 17 publications

(5 citation statements)

References 4 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The substages are divided into four groups: metastatic spread to soft tissues and lymph nodes (M1a), lung (M1b), parenchymal organs (M1c), and M2, representing any organ involvement associated with abnormal LDH levels. LDH is a prognostic serum marker associated with increased tumor burden in late-stage malignant melanoma, and has been included in the AJCC staging system as a separate substage due to its prognostic significance (28)(29)(30). Because stage IV subclassification correlates with disease severity and survival rates (28), we set out to explore the impact on MDSC levels.…”

Section: Changes In Mdsc Frequencies Correlate Only With Metastatic Smentioning

confidence: 99%

Clinical Significance of Circulating CD33+CD11b+HLA-DR− Myeloid Cells in Patients with Stage IV Melanoma Treated with Ipilimumab

Sade-Feldman

Kanterman

Klieger

et al. 2016

Clinical Cancer Research

170

117

View full text Add to dashboard Cite

show abstract

Section: Changes In Mdsc Frequencies Correlate Only With Metastatic Smentioning

confidence: 99%

Clinical Significance of Circulating CD33+CD11b+HLA-DR− Myeloid Cells in Patients with Stage IV Melanoma Treated with Ipilimumab

Sade-Feldman

Kanterman

Klieger

et al. 2016

Clinical Cancer Research

170

117

View full text Add to dashboard Cite

show abstract

“…LDH was reported to be an indicator for liver metastases, with a respective sensitivity and specificity of 95% and 83% in stage II patients, and 87% and 57% in stage III patients [31]. Patients with abnormal LDH levels had a significantly decreased survival [32]. Taken together, increasing evidence exists to demonstrate that LDH is elevated in advanced disease, predominantly in cases with liver metastases.…”

Section: Prognostic Tissue Biomarkersmentioning

confidence: 99%

Biomarkers in melanoma

et al. 2009

View full text Add to dashboard Cite

Biomarkers are tumour- or host-related factors that correlate with tumour biological behaviour and patient prognosis. High-throughput analytical techniques—DNA and RNA microarrays—have identified numerous possible biomarkers, but their relevance to melanoma progression, clinical outcome and the selection of optimal treatment strategies still needs to be established. The review discusses a possible molecular basis for predictive tissue biomarkers such as melanoma thickness, ulceration and mitotic activity, and provides a list of promising new biomarkers identified from tissue microarrays that needs confirmation by independent, prospectively collected clinical data sets. In addition, common predictive serum biomarkers—lactate dehydrogenase, S100B and melanoma-inhibiting activity—as well as selected investigational serum biomarkers such as TA90IC and YKL-40 are also reviewed. A more accurate, therapeutically predictive classification of human melanomas and selection of patient populations that would profit from therapeutic interventions are among the major challenges expected to be addressed in the future.

show abstract

“…Patients with abnormal LDH levels had a significantly decreased making LDH a prognostic factor in late-stage malignant melanoma survival [27]. Therefore, LDH is used in most clinical trials with advanced melanoma as stratification factor since it has also been shown that LDH levels be itself have a high predictive value in stage IV melanoma patients [28].…”

Section: Serum Biomarkers For Melanomamentioning

confidence: 99%

Cutaneous melanoma: A model to study cancer metastasis

Leong

Gershenwald

Soong

et al. 2011

Journal of Surgical Oncology

View full text Add to dashboard Cite

Nodal status in melanoma is a critically important prognostic factor for patient outcome. The survival rate drops to <10% when melanoma has spread beyond the regional lymph nodes and includes visceral involvement. In general, the process of melanoma metastasis is progressive in that dissemination of melanoma from the primary site to the regional lymph nodes occurs prior to systemic disease. The goal of this review article is to describe melanoma as a clinical model to study cancer metastasis. A future challenge is to develop a molecular taxonomy to subgroup melanoma patients at various stages of tumor progression for more accurate targeted treatment.

show abstract

LDH in the follow-up of stage I malignant melanoma

Cited by 17 publications

References 4 publications

Clinical Significance of Circulating CD33+CD11b+HLA-DR− Myeloid Cells in Patients with Stage IV Melanoma Treated with Ipilimumab

Clinical Significance of Circulating CD33+CD11b+HLA-DR− Myeloid Cells in Patients with Stage IV Melanoma Treated with Ipilimumab

Biomarkers in melanoma

Cutaneous melanoma: A model to study cancer metastasis

Contact Info

Product

Resources

About